Anti-clusterin monotherapy for cancer treatment
a cancer treatment and anti-clusterin technology, applied in the field of anti-clusterin monotherapy for cancer treatment, can solve the problem that custirsen is not known to be effective for the treatmen
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
example 1
In Vivo Activity of Custirsen Against RPMI 8226 (Human Myeloma) Xenograft Model, Implanted Subcutaneously into Athymic Nude Mice
Summary
[0060]This study aimed to evaluate the effect of custirsen (OGX-11, TV-1011) against human myeloma model in nude mice. The cells were implanted subcutaneously into female SCID mice with 7×106 cells inoculum. On day 20, when the tumors reached 120-170 mm3, mice were sorted into two treatment groups (n=10): control group; and custirsen 40 mg / kg ip qd*5, then twk.
[0061]Tumors and body weights were measured weekly until termination of the study on day 71. Response to treatment was evaluated for tumor growth inhibition (TGI) and tumor growth delay (TGD).
[0062]Treatment with custirsen at a dose of 40 mg / kg was stopped after 7 injections due to toxicity. Nevertheless, as a monotherapy it significantly inhibited tumor growth by the end of the study.
Introduction
[0063]The objective of this study was to evaluate the effect of custirsen (OGX-11, Tv-1011) against...
example 2
In Vivo Activity of Custirsen (TV-1011) Against RPMI 8226 (Human Myeloma) Xenograft Model, Implanted Subcutaneously into Athymic Nude Mice
[0079]A previous in-house study demonstrated that custirsen had an inhibitory effect on tumor growth, but also showed unacceptable toxicity at a high dose.
[0080]In this study custirsen is administered using a different dose and regimen in order to avoid toxicity.
Materials and Methods
Test Articles
[0081]RPMI 8226 (Human Plasmacytoma, Myeloma B Cells) ATCC # CCL-155;[0082]ECM Gel (Matrigel), Sigma-Aldrich, Cat # E1270, 5 ml;[0083]RPMI (Beit Haemek);[0084]Custirsen (TV-1011) 20 mg / ml, K-46138;[0085]Sodium chloride, TEVA.
Test Animals
[0086]120 CB.17 SCID female mice, 4-6 weeks old, 16-20 grams, obtained from Harlan animal breeding center.
Experimental Procedures
Cells Preparation
[0087]Cells (originated from ATCC) were cultured on RPMI medium. Cell suspension was centrifuged and resuspended in 50% Matrigel / HBSS to a final concentration of 7×107 cells / ml. T...
example 3
In Vivo Activity of Custirsen (OGX-11) Against PC-3 (Human Prostate Carcinoma) Xenograft Model, Implanted Subcutaneously into Athymic Nude Mice
[0100]The cells were implanted subcutaneously into female immunodeficient nude mice. On day 14, when the tumors reached 90-135=3, mice were sorted into treatment groups (n=10): 1. Control group was treated with saline i.p. qd*7+twk; 2. Custirsen treatment (25 mg / kg ip qd*5+twk).
[0101]Tumors and body weights were measured once a week until termination of the study on day 58 included. Response to treatment was evaluated for tumor growth inhibition (TGI) and expressed as the difference between the mean tumor volumes of treated and control mice.
Materials and Methods
a. Materials
[0102]PC-3 (Human Prostate Adenocarcinoma), ATCC, CAL-1435™[0103]RPMI medium 1640+L-Glutamine (Beit Haemek)[0104]Custirsen (OGX) 20 mg / ml, K-46138;[0105]The custirsen solution was prepared once weekly and stored at 4° C. 4.0 ml of the stock solution of custirsen (20 mg / ml) ...
PUM
| Property | Measurement | Unit |
|---|---|---|
| concentration | aaaaa | aaaaa |
| volume | aaaaa | aaaaa |
| volume | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More